Recovery After Fast Track THA / TKA
0-21
Prospective Descripive Study of Subacute Function After Total Hip or Knee Arthroplasty
1 other identifier
observational
112
1 country
2
Brief Summary
The development and implementation of "fast-track" principles in total knee and hip arthroplasty have resulted in early recovery and rehabilitation alongside a reduced length of hospital stay. This without a concomitant increase in morbidity or readmissions for medical or surgical complications and with reduced mortality. However, only little is known about function in the subacute period after arthroplasty, and there is a need for further data on physical and psychological functioning following discharge from hospital.This to ensure, that the positive results from the perioperative setting are carried forward in the subacute phase.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2014
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2014
CompletedFirst Submitted
Initial submission to the registry
May 12, 2014
CompletedFirst Posted
Study publicly available on registry
May 14, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2016
CompletedMarch 9, 2016
March 1, 2016
1.8 years
May 12, 2014
March 8, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Pain
VAS when walking
48 hours postoperatively
Eligibility Criteria
Patients with hip or knee osteoarthritis referred for total joint arthroplasty.
You may qualify if:
- Primary total hip or knee arthroplasty
- Age 55 to 80 years
You may not qualify if:
- Deficient written or spoken danish
- Alcohol abuse (\>21 U per week)
- Immunocompromised
- Anticoagulant therapy
- ASA class 4-5
- Functional impairment from psychological or neurological disease
- Sleepapnea
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Rigshospitalet, Denmarklead
- Lundbeck Foundationcollaborator
Study Sites (2)
Gentofte hospital
Gentofte Municipality, Capital Region, 2820, Denmark
Vejle Sygehus
Vejle, Region Syd, 7100, Denmark
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, DMSci
Study Record Dates
First Submitted
May 12, 2014
First Posted
May 14, 2014
Study Start
May 1, 2014
Primary Completion
February 1, 2016
Study Completion
February 1, 2016
Last Updated
March 9, 2016
Record last verified: 2016-03